Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
FORT LAUDERDALE, Fla., Feb. 28, 2018 -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading provider of patient-centric, clinical data management technology, signed four additional contracts in December 2017, to provide OmniComm’s proprietary TrialOne clinic automation solution to several major hospitals and contract research organizations (CROs) in China.
OmniComm now has a total of 11 TrialOne clients in China, which were all signed since December 2016, when TrialOne made its debut in that market. The deals were sparked by a strategic partnership with Tri-I Biotech (Shanghai) Inc., a market-leading China-based solutions provider to the life sciences sector.
Two years ago, OmniComm established a goal of developing a presence in the Chinese market, and to-date the company’s performance in that sector has exceeded expectations. The expanded footprint in the Asia-Pacific region includes OmniComm’s first contract for TrialMaster® in Japan, along with agreements for the use of TrialOne, TrialMaster and Promasys® in clinical studies.
“Our progression, from formulating a strategic plan two years ago to making very significant progress into the Chinese market today, has been very exciting,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “We continue to work hard on supporting our partner and our clients to ensure they are as proficient and successful as possible.”
As a system that is compliant with global industry standards and best practices for BA/BE studies and Phase I clinical research, TrialOne allows user organizations to ensure the quality and integrity of the data collected and managed during the clinical trial process. TrialOne also enables users to comply with the Chinese FDA’s new regulation and approval process for generic drug production in China. TrialOne’s ability to facilitate users’ compliance with CFDA’s regulations aimed at harmonizing local practices to global standards was also a key factor influencing the adoption of TrialOne.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations (CROs), diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Please visit www.omnicomm.com for more information.
For information about specific deals in China, please visit: http://www.omnicomm.com/blog/early-phase-research-hospitals-and-cros-sign-new-trialone-contracts-in-china
Contact Info
Kuno van der Post, Ph.D.
OmniComm Systems, Inc.
+1.954.473.1254
[email protected]
